Mechanisms of mTOR inhibitor resistance in cancer therapy
Identifieur interne : 001541 ( Main/Exploration ); précédent : 001540; suivant : 001542Mechanisms of mTOR inhibitor resistance in cancer therapy
Auteurs : Jennifer S. Carew [États-Unis] ; Kevin R. Kelly [États-Unis] ; Steffan T. Nawrocki [États-Unis]Source :
- Targeted Oncology [ 1776-2596 ] ; 2011-03-01.
English descriptors
- KwdEn :
Abstract
Abstract: Mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase that regulates cell cycle progression, protein translation, metabolism, and cellular proliferation. The mTOR pathway promotes cell proliferation under energy or nutrient-rich conditions by increasing ribosomal biogenesis and protein synthesis. Since enhanced activity of the mTOR pathway is frequently observed in malignant cells, inhibition of this kinase has become an attractive strategy to treat cancer. Rapamycin and its analogs temsirolimus, everolimus, and ridaforolimus referred to as “rapalogs” have demonstrated promising efficacy against renal cell carcinoma and are under investigation for the treatment of other malignancies. However, the emergence of drug resistance may ultimately limit the utility of rapalog therapy. Here we summarize the known mechanisms of resistance to mTOR-inhibitor therapy and describe potential strategies to overcome these for the current agents that target this pathway.
Url:
DOI: 10.1007/s11523-011-0167-8
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002956
- to stream Istex, to step Curation: 002956
- to stream Istex, to step Checkpoint: 000517
- to stream Main, to step Merge: 001543
- to stream Main, to step Curation: 001541
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mechanisms of mTOR inhibitor resistance in cancer therapy</title><author><name sortKey="Carew, Jennifer S" sort="Carew, Jennifer S" uniqKey="Carew J" first="Jennifer S." last="Carew">Jennifer S. Carew</name></author><author><name sortKey="Kelly, Kevin R" sort="Kelly, Kevin R" uniqKey="Kelly K" first="Kevin R." last="Kelly">Kevin R. Kelly</name></author><author><name sortKey="Nawrocki, Steffan T" sort="Nawrocki, Steffan T" uniqKey="Nawrocki S" first="Steffan T." last="Nawrocki">Steffan T. Nawrocki</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7E8147BB286588C6389B2EE0BBD7890D9641EB3C</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s11523-011-0167-8</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-32PKGB09-L/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002956</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002956</idno><idno type="wicri:Area/Istex/Curation">002956</idno><idno type="wicri:Area/Istex/Checkpoint">000517</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000517</idno><idno type="wicri:doubleKey">1776-2596:2011:Carew J:mechanisms:of:mtor</idno><idno type="wicri:Area/Main/Merge">001543</idno><idno type="wicri:Area/Main/Curation">001541</idno><idno type="wicri:Area/Main/Exploration">001541</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mechanisms of mTOR inhibitor resistance in cancer therapy</title><author><name sortKey="Carew, Jennifer S" sort="Carew, Jennifer S" uniqKey="Carew J" first="Jennifer S." last="Carew">Jennifer S. Carew</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, 14960 Omicron Drive, 78245, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kelly, Kevin R" sort="Kelly, Kevin R" uniqKey="Kelly K" first="Kevin R." last="Kelly">Kevin R. Kelly</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, 14960 Omicron Drive, 78245, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Nawrocki, Steffan T" sort="Nawrocki, Steffan T" uniqKey="Nawrocki S" first="Steffan T." last="Nawrocki">Steffan T. Nawrocki</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, 14960 Omicron Drive, 78245, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Targeted Oncology</title><title level="j" type="abbrev">Targ Oncol</title><idno type="ISSN">1776-2596</idno><idno type="eISSN">1776-260X</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Paris</pubPlace><date type="published" when="2011-03-01">2011-03-01</date><biblScope unit="volume">6</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="17">17</biblScope><biblScope unit="page" to="27">27</biblScope></imprint><idno type="ISSN">1776-2596</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1776-2596</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apoptosis</term><term>Autophagy</term><term>Drug resistance</term><term>PIM kinase</term><term>Rapamycin</term><term>mTOR Inhibitor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase that regulates cell cycle progression, protein translation, metabolism, and cellular proliferation. The mTOR pathway promotes cell proliferation under energy or nutrient-rich conditions by increasing ribosomal biogenesis and protein synthesis. Since enhanced activity of the mTOR pathway is frequently observed in malignant cells, inhibition of this kinase has become an attractive strategy to treat cancer. Rapamycin and its analogs temsirolimus, everolimus, and ridaforolimus referred to as “rapalogs” have demonstrated promising efficacy against renal cell carcinoma and are under investigation for the treatment of other malignancies. However, the emergence of drug resistance may ultimately limit the utility of rapalog therapy. Here we summarize the known mechanisms of resistance to mTOR-inhibitor therapy and describe potential strategies to overcome these for the current agents that target this pathway.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Carew, Jennifer S" sort="Carew, Jennifer S" uniqKey="Carew J" first="Jennifer S." last="Carew">Jennifer S. Carew</name></region><name sortKey="Kelly, Kevin R" sort="Kelly, Kevin R" uniqKey="Kelly K" first="Kevin R." last="Kelly">Kevin R. Kelly</name><name sortKey="Nawrocki, Steffan T" sort="Nawrocki, Steffan T" uniqKey="Nawrocki S" first="Steffan T." last="Nawrocki">Steffan T. Nawrocki</name><name sortKey="Nawrocki, Steffan T" sort="Nawrocki, Steffan T" uniqKey="Nawrocki S" first="Steffan T." last="Nawrocki">Steffan T. Nawrocki</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001541 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001541 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7E8147BB286588C6389B2EE0BBD7890D9641EB3C
|texte= Mechanisms of mTOR inhibitor resistance in cancer therapy
}}
| This area was generated with Dilib version V0.6.33. |  |